MacroGenics (MGNX) furnishes Q2 2025 quarterly results in 8-K filing

Rhea-AI Filing Summary

MacroGenics, Inc. filed a current report to furnish its financial and operating results for the quarter ended June 30, 2025. The company announced these quarterly results on August 14, 2025 and provided the full details in a press release attached as Exhibit 99.1.

The company states that the information in this report, including the press release, is being furnished rather than filed under securities laws. This means it is not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001125345FALSE00011253452025-08-142025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  August 14, 2025

MACROGENICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware			001-36112			06-1591613
(State or Other Jurisdiction of Incorporation)			(Commission  File Number)			(IRS Employer  Identification No.)

9704 Medical Center Drive
Rockville,			Maryland						20850
(Address of Principal Executive Offices)									(Zip Code)

Registrant's telephone number, including area code:  (301) 251-5172

Not applicable 

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.01 per share			MGNX			Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On August 14, 2025, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit Number			Description of Exhibit
99.1			Press Release dated August 14, 2025
104			Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 14, 2025			MACROGENICS, INC.
			By:			/s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel

FAQ

What did MacroGenics (MGNX) announce in this 8-K filing?

MacroGenics announced its financial and operating results for the quarter ended June 30, 2025. The detailed results are provided in a press release attached as Exhibit 99.1.

Which period do the MacroGenics (MGNX) results in this 8-K cover?

The results described relate to MacroGenics’ quarter ended June 30, 2025, as stated in the filing.

Where can investors find the detailed Q2 2025 results for MacroGenics (MGNX)?

Investors can review the full details in the company’s press release, which is attached to the report as Exhibit 99.1 – Press Release dated August 14, 2025.

Is the MacroGenics (MGNX) earnings press release considered filed with the SEC?

No. The company states that the information in this section, including Exhibit 99.1, is being furnished and not filed for purposes of Section 18 of the Exchange Act.

Does this MacroGenics (MGNX) 8-K include any other exhibits?

Yes. In addition to the press release as Exhibit 99.1, the report includes Exhibit 104, which is the cover page interactive data embedded within the Inline XBRL document.

Who signed the MacroGenics (MGNX) 8-K related to the June 30, 2025 quarter?

The report was signed on behalf of MacroGenics, Inc. by Jeffrey Peters, Senior Vice President and General Counsel.